Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Subscribe To Our Newsletter & Stay Updated